This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Kellogg (K) Set to Report Q4 Earnings: What Should You Know?
by Zacks Equity Research
Kellogg's (K) fourth-quarter results are likely to reflect strength in the snacks business and emerging markets, whereas cost inflation is likely to have been a concern.
Helen of Troy (HELE) Soars 5.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Helen of Troy (HELE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nu Skin (NUS) Up 28.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Market Edge Highlights: WBA, TROW, ITW, NUS, WSM
by Zacks Equity Research
WBA, TROW, ITW, NUS and WSM have been highlighted in this Market Edge article.
Looking for High Yields? Check the Dividend Aristocrats
by Tracey Ryniec
Getting a 5% yield isn't easy but here's some tips for finding the stocks.
Nu Skin (NUS) Dips on Q3 Earnings & Revenue Miss, View Cut
by Zacks Equity Research
Nu Skin's (NUS) third-quarter 2022 results are hurt by higher-than-anticipated macro headwinds, continued inflation, and unfavorable currency. Management lowers the full-year view.
Nu Skin Enterprises (NUS) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of -39.74% and 5.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Nu Skin (NUS) Queued for Q3 Earnings: Things to Consider
by Zacks Equity Research
Nu Skin's (NUS) Q3 performance will likely reflect continued economic uncertainty, prolonged COVID-associated factors, unfavorable currency rates and geopolitical conflicts.
Kellogg's (K) Q3 Earnings Upcoming: Here's All You Should Note
by Zacks Equity Research
Kellogg's (K) third-quarter 2022 results are likely to reflect gains from the company's revenue growth management actions, whereas cost inflation and supply-chain bottlenecks are likely to have been a concern.
Nu Skin Enterprises (NUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Nu Skin (NUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nu Skin's (NUS) Focus on Nu Vision 2025 & Product Launches Aids
by Zacks Equity Research
Nu Skin (NUS) is optimistic about its Nu Vision 2025 strategy to become the world's leading integrated beauty and wellness company, driven by a dynamic affiliate opportunity platform.
Infosys (INFY) Rides on Digitization Growth and Collaborations
by Zacks Equity Research
Infosys (INFY) continues to gain from its high-margin digital business solutions and back-to-back strategic collaboration wins.
Nu Skin (NUS) Down More Than 15% in 3 Months: Here's Why
by Zacks Equity Research
Nu Skin (NUS) is battling continued economic uncertainty, prolonged COVID-associated factors, unfavorable currency rates and geopolitical conflicts.
Nu Skin (NUS) Q2 Earnings Miss Estimates, Trims FY22 View
by Zacks Equity Research
Nu Skin's (NUS) second-quarter 2022 earnings and revenues decline year over year. Management lowers the full year view.
Nu Skin Enterprises (NUS) Q2 Earnings Lag Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of -2.53% and 0.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Factors Likely to Decide Nu Skin's (NUS) Fate in Q2 Earnings
by Zacks Equity Research
Nu Skin's (NUS) Q2 results are likely to reflect the impacts of COVID-led headwinds in Mainland China, the ongoing conflict between Russia and Ukraine, and the global economic downturn.
Inter Parfums (IPAR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Inter Parfums (IPAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Nu Skin Enterprises (NUS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nu Skin (NUS) Trims Q2 Revenue Guidance, Stock Declines
by Zacks Equity Research
Nu Skin (NUS) has been bearing the brunt of global uncertainties. Nonetheless, it believes that EmpowerMe strategy should support sequential improvements in the back half of the year.
Helen of Troy (HELE) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Helen of Troy (HELE) delivered earnings and revenue surprises of 24.23% and 8.27%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
Nu Skin (NUS) Down More Than 10% in 6 Months: Here's Why
by Zacks Equity Research
Nu Skin (NUS) has been grappling with global uncertainties like rising pandemic-related factors, unfavorable currency rates and geopolitical conflicts.
Nu Skin (NUS) Up 8.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Looks Troubled on Volatile Currency Movements
by Zacks Equity Research
Nu Skin Enterprises (NUS) has been encountering global uncertainties like rising pandemic-related factors, unfavorable currency rates and geopolitical conflicts.
Nu Skin Enterprises (NUS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 4.11% and 4.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Estee Lauder (EL) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Estee Lauder (EL) delivered earnings and revenue surprises of 14.46% and 1.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?